Table 1.
Demographic and clinical characteristics of survivors eligible for participation in the cohort study (n=544), as of January 1, 2018.
| Demographic and clinical characteristics | n (%) | ||
| Male sex | 297 (55) | ||
| Age at the time of the study (years)a | 32.5 (25.4-38.5, 18.3-56.0) | ||
| Age category at the time of the study (years) |
|
||
|
|
<20 | 30 (6) | |
|
|
20-29 | 197 (36) | |
|
|
30-39 | 207 (38) | |
|
|
>39 | 110 (20) | |
| Age at diagnosis (years)a | 6.7 (3.1-12.5, 0.1-17.5) | ||
| Age category at diagnosis (years) |
|
||
|
|
<5 | 207 (38) | |
|
|
5-9 | 134 (25) | |
|
|
10-14 | 149 (27) | |
|
|
15-19 | 54 (10) | |
| Time since diagnosis (years)a | 25.0 (17.9-32.0, 6.2-42.0) | ||
| Time since diagnosis (years) |
|
||
|
|
5-10 | 31 (6) | |
|
|
11-20 | 130 (24) | |
|
|
21-30 | 220 (40) | |
|
|
31-40 | 147 (27) | |
|
|
>40 | 16 (3) | |
| ICCC-3b cancer diagnoses |
|
||
|
|
I Leukemia | 218 (40) | |
|
|
II Lymphoma | 118 (22) | |
|
|
III CNSc | 35 (6) | |
|
|
IV Neuroblastoma | 17 (3) | |
|
|
V Retinoblastoma | 11 (2) | |
|
|
VI Renal tumor | 38 (7) | |
|
|
VII Hepatic tumor | 6 (1) | |
|
|
VIII Bone tumor | 40 (7) | |
|
|
IX Soft tissue sarcoma | 33 (6) | |
|
|
X Germ cell tumor | 8 (2) | |
|
|
XI&XII Other rare tumorsd | 20 (4) | |
| Era of treatment |
|
||
|
|
1976-1985 | 136 (25) | |
|
|
1986-1995 | 199 (36) | |
|
|
1996-2005 | 156 (29) | |
|
|
2006-2012 | 53 (10) | |
| Risk group |
|
||
|
|
High-riske | 300 (55) | |
|
|
Standard-riskf | 244 (45) | |
| Any radiation therapy | 213 (39) | ||
| Any surgery | 329 (61) | ||
| Any chemotherapy | 531 (98) | ||
| Hematopoietic stem cell transplantation | 28 (5) | ||
amedian (IQR, range).
bICCC-3, International Classification of Childhood Cancer third edition.
cCNS, central nervous system.
dincluding Langerhans cell histiocytosis, other malignant epithelial neoplasms, malignant melanomas, and other or unspecified malignant neoplasms.
eanthracyclines and/or cardiac radiation.
fany chemotherapy other than anthracyclines.